Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Aug / Only Gene Deep
Histology Histology Genetics and epigenetics Omics Oncology Precision medicine

Only Gene Deep

Advances in genomics are certainly thrilling, but let’s not forget that a tumor is more than a bundle of genetic information

08/19/2016 1 min read

Share

As histopathologists, we try to understand disease by looking at tissues. We see a snapshot of cells in their tissue environment. We can see whether they are normal or abnormal, whether there are too many or too few cells, how they are organized and how they interact. We can localize enzymes and proteins, measure expression levels, determine DNA alterations, and so on – and by bringing all this knowledge together, we can form a fairly complete picture of the disease that manifests itself in the tissue. These efforts provide the patient and the treating physician with information that can be used to choose the best possible treatment (or no treatment).

In this era of genetics, we are increasingly able to sequence the DNA of individuals and tumors, which allows us to quickly diagnose many different diseases that are caused by changes in genes, such as cystic fibrosis or Noonan syndrome. For cancers, we get information on the gene alterations that drive the tumor; for example, c-erbB2 amplification or ALK-fusions. Increasingly, it is suggested that whole genome sequencing will replace traditional forms of diagnosis. Indeed, if a child with an intellectual disability comes for a diagnosis, physical examination is already replaced by DNA analysis. And I was informed that in Hong Kong, where the incidence of EGFR mutated lung cancer is quite high compared with western countries, lung cancer is already diagnosed using genetic tests on blood samples in patients with inaccessible pulmonary lesions; if an EGFR mutation is found, it is regarded as sufficient evidence that the patient should be treated using an anti-EGFR approach. But in my view, although sequencing is an important diagnostic tool with much potential, it will never give the complete picture. An example: it was recently shown that the cells within a tumor the size of a ping-pong ball will carry a total of 100 million mutations, with only a few of those mutations present in the majority of cells (1). Not only does this finding indicate that tumor heterogeneity on the cellular level is enormous, but also that complete sequencing of tumors provides us with so much data that it becomes useless. Quite interesting, of course, but not surprising for pathologists. In fact, that the nuclei in cancer cells are extremely variable compared with normal cells has been one of the most important criteria a pathologist uses when making a diagnosis of cancer for more than a century... Furthermore, a tumor consists of not only neoplastic cells but also stromal cells, such as fibroblasts, inflammatory cells, endothelial cells and others. There is enormous variation in the ratios of these cell types between tumors – variation that has been shown to relate to treatment response and survival of the patient. Such variation cannot be found by sequencing the tumor or even the germline DNA.

Genes act through proteins, but proteins are not only modified by genetic mechanisms. Indeed, proteomic approaches are likely to give even more information, but replacing genomics with proteomics (which will take quite some time) will also not tell the whole story. Cells and tissues are so complex that we cannot fully understand what is going on by extracting only the genes and proteins. Spatial orientation, communication between cells, composition of tissues are all critical. To that end, analyzing tissues with the microscope will remain an extremely cheap and fast way of providing useful information. But I am also convinced that we can benefit from new approaches in this field to extract even more information; for instance, deep-learning approaches – where standard tissue image analysis is supplemented with new information based on automated quantification of structures and protein levels – have great potential. Of course, sequencing of tumors has given us a lot of valuable information – and will continue to do so – but we must remember that many other factors are equally important. As we all know, we are more than our genes – and a tumor is more than its genetic make-up.

Newsletters

Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. S Ling et al., “Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution”, Proc Natl Acad Sci USA, 112, E6496-505 (2015). Erratum in: Proc Natl Acad Sci USA, 113, E663 (2016). PMID: 26561581.

Explore More in Analytical Science

Dive deeper into the analytical science. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Your Newest Colleague?
Histology
Your Newest Colleague?

January 6, 2022

1 min read

The need for AI-based end-to-end biomarkers in oncology

Biospecimen Access For Biotechs
Histology
Biospecimen Access For Biotechs

February 14, 2022

1 min read

Quality, provenance, and “taking pot luck”

Case of the Month
Histology
Case of the Month

February 21, 2022

1 min read

The Art of the Laboratory
Histology
The Art of the Laboratory

March 25, 2022

1 min read

For the seventh time, we asked you to share the images you think capture the most beautiful, educational, or amusing aspects of pathology – and you delivered. Welcome to our gallery tour of the most visually striking discipline in medicine!

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.